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1. Introduction
During the past century, the diagnosis and treatment of heart failure has changed substan‐
tially.  Heart  failure,  once  viewed  primarily  as  resulting  from  rheumatic  valvular  heart
disease,  presents  currently as  the main complications of  diabetes,  viral  cardiomyopathy,
coronary artery disease, myocardial infarction and hypertension. Although the etiologies
are diverse, virtually all  instances of heart failure can be characterized by a sequence of
specific molecular changes in the myocardium. These molecular changes result in decre‐
ments in cardiac myocyte contractility (negative inotropy), the hallmark of heart failure. In
the normal heart, contractility is mainly regulated and, therefore, maintained by G protein-
coupled receptor (GPCR) signaling (Huang et al., 2011). GPCR signaling is stimulated when
neurotransmitters,  hormones and drugs possessing positive inotropic  activity bind to β-
adrenergic receptors (Leone et al., 2002). One of the main signaling problems in heart failure
is that the GPCR β-adrenoceptor kinases -2 and -5 (GRK2 and GRK5) phosphorylate the
GPCRs and make them insensitive to positive inotropic β-adrenoceptor ligands (Hata et al.,
2004). As such, phosphorylation of the GPCRs functionally uncouples them from their G-
proteins, thereby downregulating the cardiomyocyte intracellular signaling cascades which
support  myocardial  contractility.  GRK2  is  the  most  abundant  cardiac  GRK  and  GRK2
activity  is  increased in  several  cardiovascular  diseases  involving impaired cardiac  func‐
tion and heart failure (Petrofski and Koch, 2003). GRK2 regulates myocardial signaling and
heart development and the targeting of GRK activity by small molecule inhibitors of GRK2
is thought to have the potential to become an effective strategy for treatment of heart failure
(Iaccarino and Koch, 2003).
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Protein kinases and molecular mechanisms of negative inotropy and heart failure
Increased synthesis and release of endogenous β-adrenoceptor ligands such as norepinephr‐
ine, epinephrine and dopamine (catecholamines),  mediated by sympathetic neural activi‐
ty,  is  an  attempt  to  drive  the  heart  pump  to  compensate  for  heart  failure.  Another
compensation  attempts  to  drive  the  cardiac  pump  by  upregulating  the  protein  kinases
known as cAMP-dependent protein kinase (PKA), protein kinases activated by the same
signal transduction pathways as phospholipase C (PKC), phosphoinositide-3 kinases (PI3K)
and  mitogen-activated  protein  kinases  (MAPK).  These  protein  kinases  phosphorylate
intracellular  enzymes  that  are  functionally  coupled  to  the  signaling  pathways  which
produce positive inotropic effects. Another compensation attempts to drive the pump by
amplifying effects of the thyroid hormones on ion-channel and pump activities; however,
upregulation of the thyroid hormones tri-iodothyronine (T3) and tetra-iodothyronine (T4)
is also known to produce negative inotropic effects which are thought to be mediated by
a T4 metabolite, 3-iodothyronamine (Axelband et al., 2011). The amplification of the effects
of  T3and T4 results  in  protein  kinase  mediated phosphorylation of  proteins  which pro‐
mote calcium ion influx via L-type calcium channels and calcium removal by sarcoplas‐
mic reticular Ca2+ (SERCA) pumping. Calcium influx increases contractility and results in
positive inotropic effects whereas removal prevents calcium overload and, thereby, limits
negative  inotropy.  In  addition,  thyroid  hormones  increase  protein  kinase-mediated
phosphorylation of the sarcoplasmic reticular protein phospholemman. Phosphorylation of
phospholemman is reported to stimulate sarcolemmal sodium-potassium pumping, (Na+/K
+  ATPase) activity. Na+/K+  ATPase activity limits excessive depolarization associated with
increases  in  intracellular  Na+  and  may  thereby  prevent  the  arrhythmias  likely  to  be
associated with depolarization (Bers et al., 2009). Adenylyl cyclase regulates cAMP mediated
signaling and the cAMP in cardiomyocytes stimulates PKA mediated phosphorylation of
proteins  which  produces  positive  inotropic  effects  (Movsesian,  2003).  Desensitization  of
cardiac  adenylyl  cyclase  signaling  is  known  to  occur  in  heart  failure.  Whereas  such
desensitization  may  protect  against  adrenergic  overstimulation,  it  also  limits  positive
inotropy by downregulating β-adrenoceptors and by upregulating both the β-adrenocep‐
tor GRKs and the inhibitory alpha subunit of G-proteins (Gi). In turn, upregulation of β-
adrenoceptor GRKs decreases cardiomyocyte cAMP and the downstream positive inotropic
signaling effects  of  PKA (El-Armouche et  al.,  2003).  Hence,  β-adrenergic antagonists  are
very effective treatments for heart failures; however, it remains unclear whether β-adreno‐
ceptor blockers resensitize the β-adrenergic receptor system (Lohse et al., 2003).
1.2. Hormonal and immunologic mediators of negative inotropy and heart failure
Angiotensin II  (Ang II)  is  also  an important  modulator  of  myocardial  inotropy and the
inotropic effects  of  Ang II  are mediated by a balance of  positive and negative inotropic
signaling mechanisms. Heart failure is characterized by chronic exposure to high circulat‐
ing  levels  of  Ang  II  wherein  the  inotropic  balance  favors  negative  inotropy  linked  to
activation of  p38-  mitogen-activated protein kinase which is  activated by environmental
stressors such as pro-inflammatory cytokine (p38 MAPK) signaling. Ang II also plays a role
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in cardiac remodeling involving hypertrophy and apoptosis mediated by Ca2+/calmodulin
dependent protein kinase II (CaMKII) (Palomeque et al., 2009). The sarcoplasmic reticular
ryanodine receptor-2 Ca2+ release channel (RyR2) can be phosphorylated by several protein
kinases such as PKA and CaMKII (Currie, 2009). Abnormal phosphorylation of RyR2 is also
reported  to  contribute  to  the  negative  inotropy  associated  with  heart  failure.  Although
phosphorylation of RyR2 by CaMKII can produce positive inotropic effects,  upregulated
CaMKII activity may increase Ca2+  release from the sarcoplasmic reticulum, resulting in
negative  inotropy  and  cardiac  arrhythmias  (Currie,  2006).  Negative  inotropy  and  β-
adrenergic  receptor  insensitivity  may  also  result  from  production  and  release  of  the
inducible isoform of nitric oxide synthase (iNOS) (Deswal et  al.,  2001).  In addition, pro-
inflammatory cytokines such as TNF-α appear to have the capacity to produce negative
inotropy and cardiac remodeling whereby TNF-α (Levine et al., 1990) IL-6 (Kell et al., 2002)
and IL-8 (Damas et al., 2000) are reported to induce apoptosis of cardiac myocytes. High
circulating levels of IL-6 are associated with low cardiac muscle contractility and high levels
of TNF-α have been found to be negatively correlated with a favorable clinical outcome of
heart  failure  patients.  The  negative  inotropy,  remodeling  (hypertrophy)  and  apoptosis
associated with exposures to TNF-α seem to be mediated by activation of TNF receptor-1
(TNFR1) and inhibited by stimulation of TNF receptor-2 (TNFR2). Activity of both TNFR1
and TNFR2 are reported to be upregulated in heart failures (Chrysohoou e tal., 2009; Hamid
et al., 2009). Stimulation of TNFR1 is shown to have the capacity to downregulate the rapid
delayed-rectifier K+ current (IKr) and, thereby, to delay cardiac repolarization, increasing the
duration of the cardiac action potential  in cardiomyocytes (Wang et al.,  2004).  Increased
duration of the ventricular action potential is thought to be an attempt to maintain cardiac
muscle contractility and limit the negative inotropy associated with heart failure. We have
reported insensitivity to an agonist and to an antagonist of KATP  channels,  which would
serve to limit the aforementioned increased duration of the ventricular action potential, in
cardiomyocytes undergoing eccentric  hypertrophic  remodeling after  volume overloading
such as that which could occur during the development of heart failure associated with
aortic valve regurgitation (Alvin et al.,  2011). However, this increased duration of action
potential also increases susceptibility to cardiac arrhythmia in hypertrophy-induced heart
failure. Increased duration of the cardiac action potential is also observed in the TNF1.6
mouse model in which heart failure is produced by overexpression of TNF-α. Therefore, it
seems  that  TNF-α  induced  increments  in  duration  of  the  cardiac  action  potential  and
insensitivity to mechanisms that could limit the increased action potential duration may be
important features of the hypertrophic remodeling associated with heart failures. Another
mechanism for  TNF-α induced negative  inotropy  is  thought  to  result  from overexpres‐
sion of collagen and underexpression of the gap junction protein connexin-43 (Janczewski
et al., 2004).
1.3. Intracellular transduction molecules, negative inotropy and heart failure
Myocardial infarction in mice together with estrogen receptor-β knockout is reported to
increase the cardiomyocyte MAPK activities of the c-Jun, N-terminal kinase (JNK) activator
protein-1 (AP-1) transcription factor component. These signaling molecules are activated by
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environmental stressors such as pro-inflammatory cytokines in females and the MAPK
extracellular signal-related kinases (ERK1 and ERK2 also known as MAPK3 and MAPK1,
respectively), cell-proliferation, growth-promoting signaling pathway in males. Estrogen
protection of the myocardium associated with upregulated PI3K and the original mouse-strain
Ak, thymic lymphoma transforming (Akt) cell proliferation and anti-apoptosis signaling
activities in female mice suggests deficiencies of ER-β and PI3K/Akt mediated anti-apoptosis
signaling in such infarction induced heart failures (Wang et al., 2009). Cardiomyocyte protec‐
tion by adrenomedullin, a vasoactive peptide discovered in pheochromacytomas, also appears
to involve upregulated PI3K/Akt and MAPK/ERK signaling pathways (Yanagawa and
Nagaya, 2007). The myocardial protection reported with ginseng and related ginsenoside
treatments are likely to decrease negative inotropy and the duration of cardiac action poten‐
tials, arrhythmias, remodeling and apoptosis by interactions with these protein kinases
(Maslov and Konkovskaia, 2009). We have reported that MAPK ERK and PI3K/Akt signaling
molecules play important roles in eccentrically-hypertrophied rat hearts subjected to volume
overload (Teos et al., 2008; Zhao et al., 2010; Alvin et al., 2011). Substantial evidence is,
therefore, emerging that the protein kinases in cardiomyocytes are invaluable biomarkers for
heart failure, as well as for the effectiveness of cardiac protection by novel heart failure
treatments.
2. Epigenetics, chromatin condensation for transcription and protein
kinases
Chromatin participating in the transcription of DNA to mRNA is represented in the nucleus
of eukaryotic cells by euchromatin, a lightly staining, unfolded structure which facilitates
binding  to  the  DNA of  various  gene  regulatory  proteins  and  RNA polymerases  which
induce  transcription.  The  euchromatin  that  is  not  transcribed  is  transformed  into  more
tightly and intensely staining heterochromatin which appears to protect the genes while
they are not being actively transcribed. According to the “accessibility hypothesis,” the cell
uses transformation from euchromatin to heterochromatin as a method of regulating the
expression and replication of genes (Yancopoulos et al., 1986). Constitutive euchromatin is
the portion that is always being actively transcribed, thereby representing “housekeeping
genes” which encode proteins supporting the cell survival functions (International Human
Genome Sequencing Consortium,  2004).  The condensation of  chromatin for  transcription is
regulated  by  epigenetic  modifications  made  to  DNA,  histones  and  to  other  regulatory
proteins (Martin and Cardoso, 2010).
Epigenetics at work in the normal heart is demonstrated by the regulation of cyclic AMP-
dependent protein kinase (protein kinase A, PKA), a positive-inotropic agent in cardiac
myocytes and related heart tissue cells. PKA induces relaxation of the histone-3 and histone-5
(H3 and H5) associated DNA segments which condense the chromatin for transcription of the
structural and functional proteins supporting normal cardiomyocyte contractility (Marion et
al., 1985).
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2.1. Epigenetic marks for monitoring cardiovascular disease progression
A potential use of epigenetic modifications on histones and related DNA segments is to
provide a code sensitive to the progression of diseases that are impacted by environment-gene
interaction. An example of this usage of epigenetic marks has been demonstrated in patients
with end-stage heart failure. Heart failure in these patients appears to be correlated with
differential methylation of the DNA and histones at lysine residue 36 (H3K36me3) in their
cardiomyocytes. (Movassagh et al., 2011). Another example of how epigenetic marks can be
useful is reported in cardiac hypertrophy wherein mRNA expression of multiple cardiomy‐
opathy-related genes was found to be associated with a unique, specific pattern of acetylation
and methylation of histone H3 in the cardiomyocytes (Gaikwad et al., 2010).
3. Histone acetylation/methylation and cardiomyopathy
3.1. Repressor element-1 silencing transcription factor (REST) and cardiomyocyte
hypertrophy
Cardiomyocyte hypertrophy is a compensatory response to maintain contractility and heart
function. Inhibition of expression of the gene for repressor element-1 silencing transcription
factor (REST), a fetal gene transcription repressor in adult ventricular myocytes (Schoenherr
and Anderson, 1995), has been linked to cardiomyocyte hypertrophy (Bingham et al., 2007).
Endothelin-1 is an endogenous vasoconstrictor molecule known to be a stimulator of cardio‐
myocyte hypertrophy (Harada et al., 1997; Drawnel et al., 2013). Treatment of cardiomyoblast
(H9C2) cells with endothelin-1 is shown to inhibit REST and the amount of hypertrophy seems
to be positively correlated with acetylation of histone H4 and methylation of histone H3 lysine
4 (H3K4) (Bingham et al., 2007). Endothelin-1 also appears to employ REST to increase
expression of the genes for brain and atrial natriuretic peptides, hormones that help compen‐
sate for heart failure by decreasing the circulating blood volume (Bingham et al., 2007).
3.2. Histone deacetylase GATAD1 and cardiomyopathy
Autosomal-recessive dilated cardiomyopathy in a human family has been shown to be
associated with abnormal expression and subcellular localization of GATAD1 (Theis et al.,
2011). GATAD1 is a gene product that is highly expressed during embryonic development of
the mouse eye (Kim et al., 2010) and is a regulator of gene expression in cardiomyocytes.
GATAD1 appears to function as a histone deacetylase, evidenced by its binding to a histone
modification site (Theis et al., 2011). Interestingly, dilated cardiomyopathy has been produced
in mice following inhibition of histone deacetylases (Theis et al., 2011). Deletion of histone
deacetylase-3 (HDAC3) in embryonic cardiomyocytes is associated with a nonlethal cardiac
hypertrophy and cardiomyopathy induced while animals are fed a normal diet. However,
more severe hypertrophy, cardiomyopathy and heart failure occurs when these animals are
fed a high-fat diet, associated with downregulation of several genes which regulate lipid
metabolism (Sun et al., 2011).
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3.3. DNMT inhibition, gene methylation, cardiomyocyte differentiation and
cardiomyopathy
Decreased availability of β-catenin is expected to decrease developmental Wnt pathway
transcription, an effect shown to be associated with inhibition of cardiomyocyte hypertrophy
and left ventricular remodeling in animal models of heart failure (Bergmann, 2010). DNA
methyltransferases (DNMT) are epigenetic regulators of cell differentiation and metabolism
and treatment of mesenchymal stem cells with the DNMT inhibitor and demethylating agent
5-aza-2’-deoxycytidine (5-Aza) is shown to induce expression of the cardiac tissue-specific
genes Nkx2.5 and α-MHC. 5-Aza treatment also upregulates glycogen synthase kinase-β
(GSK3β) and downregulates the cell adhesion protein β-catenin, whereas it increases expres‐
sion of GSK3α. This upregulation of GSK3β also stimulates cardiomyocyte differentiation (Cho
et al., 2009). That GSK3 inhibitors (e.g., lithium) were found to be effective at blocking this 5-
Aza induced upregulation implies that GSK3 is required for cardiomyocyte differentiation.
That downregulation of β-catenin is closely associated with GSK3β-stimulated cardiomyocyte
differentiation (Cho et al., 2009) suggests an unclear relationship between β-catenin and
GSK3β and a significant difference between the 5-Aza induced mechanisms for differentiation
of mesenchymal stem cells and the DNMT-dependent mechanism for inhibiting cardiomyo‐
cyte hypertrophy, ventricular remodeling and heart failure.
3.4. Methylation of PKCε and heart failure
Epidemiological studies have suggested correlations between prenatal exposure to adverse
intrauterine conditions and risk for ischemic heart disease, a primary cause of heart failure, in
adulthood. Hypoxia is a fetal stress known to decrease expression of the PKCε gene and
increased susceptibility to myocardial ischemia and reperfusion injury in adult rat offspring
(Xue and Zhang, 2009). This predilection for myocardial ischemia is associated with increased
methylation of the PKCε promoter at two fetal transcription factor specific protein-1 (Sp1)
binding sites. Hypoxia seems to affect the binding of Sp1 only to methylated, and not to
unmethylated, sites. However, methylation of both Sp1 sites seems to decrease PKCε binding
to Sp1 in both fetal and adult cardiomyocytes (Xiong et al., 2012). The DNMT inhibitor 5-Aza
has been shown to block the hypoxia-induced increase in methylation of both Sp1 binding sites
and to restore PKCε mRNA and protein levels to normal. These effects appear to be greater in
male than in female fetal hearts. Decreased expression of PKCε mRNA was found only in the
male hearts, with interactions between both estrogen receptor proteins and the Sp1 binding
site (Patterson et al., 2010). Moreover, activation of PKCε is reported to cause return of high
susceptibility of adult rat hearts to ischemic injury following prenatal exposure to hypoxia
(Patterson et al., 2010). PKCε is also an activator of ATP-activated potassium (KATP) channels,
a metabolic energy conservation measure associated with reduced energy supply stress in
cardiomyocytes (Kim et al., 2006). PKCε induced KATP activation is reported to shorten the
cardiomyocyte action potential and limit calcium ion influx and overload in cardiac myocyte
sarcolemmal and mitochondrial membranes (Inagaki et al., 2006). PKCε also seems to mediate
ischemic preconditioning, a cardioprotective countermeasure against myocardial ischemia/
infarction (Inagaki et al., 2006).
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Epigenetically-induced decrements in expression of PKCε, associated with aberrant methyl‐
ation patterns, are also reported in relation to heart failure following experimental exposures
to cocaine and nicotine (Barik, 2007). Prenatal exposure to cocaine is reported to downregulate
PKCε expression in hearts, effects which persist into adulthood and increase susceptibility to
myocardial ischemia and infarction and reperfusion injury (Zhang et al., 2007). Cocaine
treatment of the fetal rat heart for as little as 48 h produces significant decrements in PKCε
protein and mRNA expression, associated with increases in CpG methylation at two binding
sites of the Sp1 in the PKCε promoter region, confirmed by the use of the DNMT inhibitor 5-
Aza or procainamide to inhibit this methylation (Meyer et al., 2009). Moreover, cocaine
administered to pregnant rats during gestational days 15-20 produced offspring whose fetal
hearts had significantly decreased expression of PKCε mRNA and protein. We have shown
that IGF-1 antagonizes the positive-inotropic effect of Ang II in atrial myocytes of aging male
rats and that prenatal exposure to cocaine abolishes this response (Haddad et al., 2005), an
effect that could also be mediated by decreased expression of PKCε. In addition, methylation
of CpGs at the binding sites for activator protein-1 (Ap1), a human protein transcription factor,
was decreased in these fetal hearts and was increased significantly by prenatal exposure to
cocaine (Zhang et al., 2007). The CpG dinucleotides at Bhlhb2, Pparg, E2f, and Egr1 binding
sites of the PKCε gene promoter are reported to be densely methylated in both male and female
adult rats and prenatal exposure to cocaine appears to decrease methylation of the CpG
dinucleotides at the two Sp1 binding sites and this binding was increased significantly by
cocaine exposure, but only in the male offspring (Zhang et al., 2009).
Interestingly, prenatal exposure to nicotine, which increases release of norepinephrine, is also
associated with inhibition of PKCε gene expression in the fetal rat heart, an effect which, like
cocaine, persists into adulthood (Lawrence et al., 2008). This finding appears to link maternal
smoking to heart failure in the offspring. Nicotine treatment of pregnant rats starting at day 4
of gestation is shown to increase methylation of the Egr-1 binding site at the PKCε gene
promoter and decrease PKCε protein and mRNA expression in fetal hearts (Lawrence et al.,
2011). Moreover, methylation of the Egr-1 binding site decreases Egr-1 binding to the PKCε
promoter and cardiomyocyte deletion of the Egr-1 binding site decreases PKCε promoter
activity and treatment of isolated fetal hearts with norepinephrine produces similar effects
including increased Egr-1 binding site methylation and inhibition of PKCε gene expression.
The DNMT inhibitor 5-Aza inhibited the norepinephrine-induced increase in methylation of
the Egr-1 binding site and restored both Egr-1 binding and PKCε gene expression, implicating
sympathetic neural overactivity in this nicotine-induced heart failure (Lawrence et al., 2011).
3.5. TNF-α methylates SERCA genes and inhibits cardiac relaxation
The aforementioned epigenetic mechanisms for heart failure are relevant mainly to the
negative inotropy associated with heart failure resulting from systolic dysfunction and the
majority of current treatments at increasing contractility to counteract systolic dysfunction.
However, heart failure associated with diastolic dysfunction may be more common and most
heart failure is, therefore, resistant to current treatments and may contribute to ethnicity-
related predilections for heart failure in specific populations such as African-Americans (Khan
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et al., 2012). The focus of diastolic dysfunctional heart failure is an inability of cardiomyocytes
to relax, a function critical to ventricular filling and, according to Starling’s law of the heart,
maintenance of contractility and stroke volume. In that regard, treatment with the pro-
apoptotic cytokine tumor necrosis factor-α (TNF-α) is reported to methylate and decrease the
cardiomyocyte sarcoplasmic reticulum calcium pump (SERCA-2A) gene activity, mRNA
expression and protein transcription, thereby providing an epigenetic mechanism for diastolic
heart failure (Kao et al., 2010). The promoter region of the SERCA-2A gene has a high content
of CpG islands and treatment with the antihypertensive, smooth muscle relaxer apresoline,
commonly used in cases of human heart failure, is reported to improve cardiac function in rat
hearts by the mechanism of demethylating and increasing SERCA-2A gene expression of
mRNA and protein and, thereby, improving cardiac relaxation, a key factor in heart failure
associated with diastolic dysfunction (Kao et al., 2011).
3.6. Methylation patterns, cardiomyocyte apoptosis and cardiomyopathy
Aberrant methylation patterns also appear to play roles in myotonic dystrophy, a group of
multisystemic diseases characterized by cardiac conduction abnormalities and CTG expan‐
sions. These CTG expansions are found to be substantially larger in cardiomyocytes than in
cells of other affected tissues. The expanded repeat is reported to be a genetic biomarker for
methylation wherein the CpG-free expanded CTG repeat appears to maintain a distinct pattern
of CpG methylation at the myotonic dystrophy (DM1) locus, which varies markedly with age
and tissue-specificity (López Castel et al., 2011). Promoter DNA methylation and Sp1 binding
are also reported to be regulators of expression of human myotonic dystrophy kinase-related
Cdc42 binding kinases (MRCKs) and family members of human myotonic dystrophy kinase
(DMPK), RhoA-binding kinase(ROK), and citron kinase (Ng et al., 2004). These findings
demonstrate an important interaction between epigenetic methylation marks (CpG-free
expanded CTG repeats) and a genetic skeletal muscle disease that often produces cardiac
anomalies.
Epigenetic mechanisms are also apparent in diabetic cardiomyopathy, another common cause
of heart failure. Tumor suppressor protein p53-induced expression of the cyclin dependent
kinasae inhibitor p21(WAF1/CIP1) is a mediator of cell cycle arrest at the G1 phase (Harper et
al., 1993). When cardiomyocytes from diabetic patients and rats are subjected to oxidative
stress, the change in methylation pattern and overexpression of p21(WAF1/CIP1) appears to
contribute to cardiomyopathy by inducing cardiomyocyte apoptosis (Mönkemann et al., 2002).
Methylation of the insulin receptor IGF-1 and IGF-1 receptor genes at their promoter regions
in cardiomyocytes of diabetic (db/db) mice is reported to be substantial and may, therefore,
function as epigenetic markers for the development of diabetic cardiomyopathy. Unfortu‐
nately, their methylation patterns seem to be inadequate for differentiating db/db diabetic
cardiomyocytes from those of normal control animals (Nikoshkov et al., 2011). On the other
hand, the methylation patterns of three angiogenesis-related genes (angiomotin-like-2, Rho
GTPase activating protein-24 and platelet/endothelial cell adhesion molecule-1) is reported to
be able to differentiate left ventricular cardiomyocytes of normal control subjects from those
of patients diagnosed with idiopathic end-stage cardiomyopathy (Movassagh et al., 2010).
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3.7. Acetylation, cardiomyocyte survival and stress-apoptosis signaling
Stress and cardiomyocyte hypertrophy are associated with lysine acetylation of many different
proteins, including histones. Lysine 53 of p38 mitogen-activated protein kinase (MAPK)
appears to be acetylated and activated by histone deacetylase-3 (HDAC3) which increases the
affinity of p38 MAPK for ATP, in parallel with decreased intracellular ATP concentrations in
cardiomyocytes undergoing stress and hypertrophy (Pillai et al., 2011). In hypertrophied
cardiomyocytes, phosphorylation of HDACs, specifically those shuttled between nucleus and
cytoplasm by HDAC kinases, is associated with disinhibition of various transcription factors
such as nuclear factor of activated T-cells and myocyte enhancer factor-2 (MEF2). On the other
hand, the antioxidant thioredoxin 1 (Trx1) is shown to inhibit cardiomyocyte hypertrophy by
decreasing cysteine residues in HDACs (Oka et al., 2009), thereby demonstrating a putative
HDAC-dependent epigenetic mechanism for oxidative stress in cardiac hypertrophy and
associated heart failure.
3.8. Lysine acetylation, shear stress and endothelial cell apoptosis
Blood vessel wall stress appears to be a potent epigenetic activator of sarcomeric protein
transcription  in  vascular  smooth  muscle  cells,  a  likely  environment-gene  interaction
contributor  to  hypertension,  the  hallmark  of  cardiovascular  disease  and  an  important
precursor to heart failure. In that regard, blood vessel wall shear stress is shown to enhance
the lysine acetylation of  histone H3 at  position 14 (K14),  as well  as serine phosphoryla‐
tion at position 10 (S10) and lysine methylation at position 79 (K79), and cooperated with
trichostatin (TSA), an antifungal agent that is also an HDAC inhibitor,  inducing acetyla‐
tion  of  histone  H4  and phosphoacetylation  of  S10  and  K14  of  histone  H3.  In  addition,
endothelial stem cells exposed to shear stress appear to strongly activate transcription from
the  vascular  endothelial  growth  factor  (VEGF)  receptor  2  promoter.  This  effect  was
paralleled by an early induction of smooth muscle actin, smooth muscle protein 22-alpha,
platelet-endothelial  cell  adhesion  molecule-1,  VEGF  receptor-2,  myocyte  enhancer  fac‐
tor-2C (MEF2C),  and α-actin.  Moreover,  the transcription factors MEF2C and Sma/MAD
homolog  protein  4  were  isolated  from  shear  stress-treated  embryonic  stem  cells  com‐
plexed with the cAMP response element-binding protein acetyltransferase (Illi et al., 2005).
HDAC3 is known to play a crucial role in the differentiation of endothelial cells (Spallot‐
ta et al., 2010). In mature endothelial cells, HDAC3 appears to be a pro-survival molecule
by activating the Akt intracellular signal transduction pathway (Zampetaki et al., 2010) and
when HDAC3 is  downregulated in  apolipoprotein E-knockout  mice,  atherosclerosis  and
rupture is found in the isografted vessels (Zeng et al.,  2006). However, at aortic bifurca‐
tions,  where  the  endothelial  cells  are  highly  susceptible  to  atherosclerosis,  HDAC3
expression  is  increased  with  phosphorylation  of  HDAC3  at  serine/threonine.  HDAC3
appears to bind to Akt and upregulates HDAC3 to increase phosphorylation of Akt in these
endothelial cells. Increased Akt kinase activity combined with knockdown of HDAC3 could,
therefore,  promote  both  atherosclerosis  and  endothelial  cell  apoptosis  by  epigenetic
mechanisms (Zampetaki et al., 2010). Such epigenetic mechanisms for endothelial dysfunc‐
tion appear to be important, yet poorly understood, contributors to cardiovascular disease
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which is found to be correlated with ethnicity and may, therefore, help explain health and
disease disparities such as the predilections for hypertension and heart failure in African-
Americans (Khan et al., 2012).
A number of studies, during the past decade or so, have shown that HDAC inhibitors may be
effective as inhibitors of cardiomyocyte hypertrophy. Class I HDACs are shown to inhibit
cardiomyocyte hypertrophy associated with inhibition of the gene encoding dual-specificity
phosphatase 5 (DUSP5) DUSP5, a nuclear phosphatase that downregulates hypertrophic
signaling by ERK1/2 (Ferguson et al., 2013). Expression of DUSP5 in cardiomyocytes produces
inhibition of hypertrophy resulting from administering prohypertrophic factors (Ferguson et
al., 2013). Inhibition of DUSP5 by class I HDACs requires activity of both ERK and MAPK, that
has been characterized as a self-reinforcing mechanism for promotion of cardiac ERK signaling
(Ferguson et al., 2013). Moreover, in cardiomyocytes treated with highly selective class I HDAC
inhibitors, nuclear ERK1/2 signaling is suppressed in a manner that is shown to be dependent
on DUSP5. Research on HDAC inhibitors as therapeutic agents for heart failure has focused
on the left ventricle. However, there is also research demonstrating that HDAC inhibitors may
also be able to treat right heart failure by mechanisms that decrease pulmonary arterial smooth
muscle contractility. A specific benzamide class I HDAC inhibitor, MGCD0103 is shown to
decrease pulmonary arterial pressure more dramatically than the type 5 cGMP phosphodies‐
terase inhibitor and vasodilator tadalafil, a standard-of-care therapy for human pulmonary
hypertension (Cavasin et al., 2012). Although this class I HDAC inhibitor only modestly
reduced right ventricular hypertrophy, it had multiple beneficial effects on the right ventricle,
which included suppression of pathological gene expression, inhibition of proapoptotic
caspase activity, and repression of proinflammatory protein expression (Cavasin et al., 2012).
4. Therapeutic potential of HDAC inhibitors
Although the findings that cardiomyocytes expressing an HDAC mutation lack phosphory‐
lation sites and are refractory to the development of hypertrophy (Zhang et al., 2002), mutant
mice lacking the class II HDAC HDAC9 do exhibit stress-induced cardiomyocyte hypertrophy
(Antos et al., 2003). These findings, although somewhat confounding, at least, suggest that
modulating specific kinase activities could be key to elucidating the mechanisms of cardiac
hypertrophy, as well as to developing novel heart failure treatments. Class II HDACs are
known to inhibit the activity of myocyte enhancer factor-2, a mediator of responsiveness to
environmental stressors and cardiac hypertrophy by binding to a stress-responsive kinase that
is specific for conserved serines. (Zhang et al., 2002). The antiepileptic drug valproic acid is a
class II HDAC inhibitor shown to inhibit the catalytic activity of HDAC6 (Lemon et al., 2011).
Both HDAC6 and HDAC8 are apparently upregulated in experimental animal models of salt
(DOCA)-sensitive hypertension and valproic acid is also shown to be an inhibitor of cardiac
hypertrophy in hypertensive rats (Kee et al., 2013). PKC signaling is shown to support nuclear
export of class II HDAC5 in cardiomyocytes and inhibition of PKC prevents shuttling of
HDAC5 from nucleus to cytosol by a chromosome region maintenance protein (CRM1, also
known as transportin-1) in response to a number of agents that promote cardiomyocyte
hypertrophy (Vega et al., 2004). An HDAC5 mutant that cannot be phosphorylated is also
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refractory to PKC signaling and inhibits cardiomyocyte hypertrophy mediated by PKC
agonists. These findings are consistent with those that demonstrate protein kinase D (PKD)
phosphorylation and enhancement of HDAC5 nuclear export because PKD is a downstream
effector of PKC (Vega et al., 2004). HDAC5 is only one of several transcriptional regulators of
pathological cardiac hypertrophy the activities of which are regulated by subcellular distri‐
bution. For example, transcription factors belonging to the nuclear factor of activated T cells
(NFAT) and GATA families of transcription factors that specifically bind to the GATA
sequences of DNA are subject to CRM1-dependent nuclear export (Harrison et al., 2004). These
pro-hypertrophic proteins are rapidly relocalized to the nucleus in response to pro-hypertro‐
phic growth signaling ( Harrison et al., 2004). CRM1 activity is, apparently, not required for
the normal cardiomyocyte gene activation mediated by thyroid hormones (T3, T4) and IGF-1,
agonists that fail to trigger the nuclear export of HDAC5. These results suggest a selective role
for CRM1 in disinhibition of pathological cardiac hypertrophy and that targeting CRM1-
dependent nuclear export in cardiomyocytes may ameliorate stress induced cardiomyocyte
hypertrophy and provide novel therapeutic strategies for heart failure (Harrison et al., 2004).
5. Summary and conclusions
Heart failure is the result of complex environment-gene interactions between regulators of
intracellular transduction molecules, intracellular/extracellular receptors and endocrine/
paracrine/ autocrine hormone-like signaling molecules. Figure 1 summarizes the main
epigenetic mechanisms of cardiomyocyte hypertrophy, negative inotropy and heart failure.
β-adrenoceptor activation of PKA is shown to interact directly with histones and related DNA
segments at promoter regions of genes for mRNA transcription to support normal cardiac
contractility. Prenatal exposures to hypoxia, cocaine or nicotine produces predilections for
heart failure shown to persist into adulthood, associated with increased methylation and
decreased expression of PKCε. Norepinephrine is also shown to decrease expression of PKCε,
thereby implicating sympathetic overactivity in an epigenetic mechanism for cardiomyocyte
hypertrophy and heart failure. Inhibition of a cardiomyocyte differentiation signaling mole‐
cule REST by endothelin-1 is shown to contribute to cardiomyocyte hypertrophy. An autoso‐
mal-recessive dilated cardiomyopathy is associated with HDAC inhibition produced by
upregulation of another differentiation signaler, GATAD1. Hypermethylation of SERCA-2A
gene by the pro-inflammatory cytokine TNF-α is shown to produce diastolic dysfunction, a
common cause of heart failure in African-Americans and particularly resistant to current
treatments. Lithium-induced inhibition of DNMTs appears to induce hypomethylation which
upregulates GS3Kβ, associated with downregulation of β-catenin and inhibition of Wnt
pathway signaling for differentiation, providing a mechanism for inhibiting cardiac hyper‐
trophy and heart failure. HDAC-dependent mechanisms for stimulating stress-apoptosis
pathway signaling and inducing cardiac hypertrophy have been demonstrated in cardio‐
myoctes, endothelial cells and vascular smooth muscle cells. These findings demonstrate
multiple roles of histone and related DNA acetylations and methylations for regulating
cardiomyocyte contractility. These epigenetic mechanisms provide insights that could be
translated to novel clinical interventions for the prevention and treatment of heart failure.
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Figure 1. Main mechanisms for epigenetic alterations in heart failure. Each alteration involves many enzymes but the
main players to cause methylation or acetylation are shown by arrows. These are not separate mechanisms and the
enzymes do not act alone. Several enzymes act at a promoter simultaneously. 1) DNA methylatrasferase (DNMT) upre‐
gulation with S-adenosyl methionine (SAM) methylates the CpG islands at the PKCε promoter region which increases
susceptibility of neonatal and adult cardiomyocytes to ischemia after prenatal exposure to hypoxia, cocaine or nico‐
tine. 2) Upregulation of DNMTs is also associated with SERCA-2A gene hypermethylation which increases diastolic dys‐
function and susceptilibity to heart failure. 3) Estrogen receptor binding to Sp1 fetal transcription factor binding sites
(S) upregulates histone methyltransferases (HMTs) which protects cardiomyocytes from downregulation of PKCε ex‐
pression. 4) Histone deacetylase-3 (HDAC3) upregulation is associated with expression of GATAD1, a fetal transcrip‐
tion factor, associated with autosomal-recessive dilated cardiomyopathy in humans and in animal models of
cardiomyopathy and heart failure. 5) Histone acetylases (HACs) and histone methyltransferases (HMTs) are upregulat‐
ed at a vascular endothelial growth factor (VEGF) promoter region by exposure of adult endothelial cell (EC) and em‐
bryonic stem cells to shear stress. Cardiomyocyte pro-hypertrophy factors include thyroid hormones (T3, T4), Ca2+
overload, protein kinase A (PKA) binding to histones, endothlein-1 (ET-1) inhibition of the gene for repressor ele‐
ment-1 silencing transcription factor (REST-1), REST gene acetylation at histone H4 and methylation at histone H3, up‐
regulation of fetal transcription factor GATAD1, inhibition of HDAC3 and activation of p38 MAPK.
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